2Seventy Bio Company Overview
About 2Seventy Bio
2Seventy Bio (NASDAQ:TSVT) is a biotech company focused on innovating in the field of cell therapy to address cancer. With a commitment to transforming cancer treatment, 2Seventy Bio develops a variety of cutting-edge projects aimed at harnessing the power of the body's immune system to fight cancer more effectively. The company's objective centers around advancing their research and development pipeline to bring novel therapies to market, offering hope and potentially more effective treatment options to patients battling various forms of cancer. Through strategic collaborations and a dedication to scientific excellence, 2Seventy Bio strives to unlock new possibilities in oncology, aiming to improve outcomes and the quality of life for those affected by cancer.
Snapshot
Operations
Products and/or services of 2Seventy Bio
- ABECMA, the first FDA-approved CAR T cell therapy for relapsed or refractory multiple myeloma, focusing on advanced blood cancer treatments.
- A broad pipeline of cell therapies aimed at various cancers, utilizing innovative T cell engineering and editing techniques.
- Collaboration with bluebird bio for oncology-focused research and development, enhancing capabilities in gene and cell therapy.
- Development of bb21217, a next-generation CAR T therapy with improved antitumor activity and persistence for treating multiple myeloma.
- Research in bispecific antibodies for dual-targeting of cancer cells, expanding the therapeutic strategies beyond CAR T therapy.
- Investment in cutting-edge manufacturing facilities to support the development and commercialization of cell therapies.
2Seventy Bio executive team
- Mr. William D. Baird III, M.B.A.CEO, President & Director
- Ms. Victoria EatwellChief Financial Officer
- Ms. Jessica SnowChief Operating Officer